Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.
Publication
, Journal Article
Lüftner, D; Lyman, GH; Gonçalves, J; Pivot, X; Seo, M
Published in: Target Oncol
December 2020
The article Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.
Duke Scholars
Published In
Target Oncol
DOI
EISSN
1776-260X
Publication Date
December 2020
Volume
15
Issue
6
Start / End Page
805
Location
France
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Lüftner, D., Lyman, G. H., Gonçalves, J., Pivot, X., & Seo, M. (2020). Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3. Target Oncol, 15(6), 805. https://doi.org/10.1007/s11523-020-00761-7
Lüftner, Diana, Gary H. Lyman, João Gonçalves, Xavier Pivot, and Minji Seo. “Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.” Target Oncol 15, no. 6 (December 2020): 805. https://doi.org/10.1007/s11523-020-00761-7.
Lüftner D, Lyman GH, Gonçalves J, Pivot X, Seo M. Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3. Target Oncol. 2020 Dec;15(6):805.
Lüftner, Diana, et al. “Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.” Target Oncol, vol. 15, no. 6, Dec. 2020, p. 805. Pubmed, doi:10.1007/s11523-020-00761-7.
Lüftner D, Lyman GH, Gonçalves J, Pivot X, Seo M. Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3. Target Oncol. 2020 Dec;15(6):805.
Published In
Target Oncol
DOI
EISSN
1776-260X
Publication Date
December 2020
Volume
15
Issue
6
Start / End Page
805
Location
France
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis